Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma
- PMID: 23408974
- PMCID: PMC3567053
- DOI: 10.1371/journal.pone.0055362
Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma
Abstract
The phosphatidylinositol 3-kinase (PI3K)/AKT pathway is activated in multiple cancers including ovarian carcinoma (OC). However, the relative contribution of the single components within the PI3K pathway to AKT activation in OC is still unclear. We examined 98 tumor samples from Italian OC patients for alterations in the members of the PI3K pathway. We report that AKT is significantly hyperactive in OC compared to normal tissue (n = 93; p<0.0001) and that AKT activation is preferentially observed in the elderly (>58 years old; n = 93; p<0.05). The most frequent alteration is the overexpression of the p110α catalytic subunit of PI3K (63/93, ∼68%); less frequent alterations comprise the loss of PTEN (24/89, 27%) and the overexpression of AKT1 (18/96, 19%) or AKT2 (11/88,12.5%). Mutations in the PIK3CA or KRAS genes were detected at lower frequency (12% and 10%, respectively) whereas mutations in AKT1 or AKT2 genes were absent. Although many tumors presented a single lesion (28/93, of which 23 overexpressed PIK3CA, 1 overexpressed AKT and 4 had lost PTEN), many OC (35/93) presented multiple alterations within the PI3K pathway. Apparently, aberrant PI3K signalling was mediated by activation of the canonical downstream AKT-dependent mTOR/S6K1/4EBP1 pathway and by regulation of expression of oncogenic transcription factors that include HMGA1, JUN-B, FOS and MYC but not by AKT-independent activation of SGK3. FISH analysis indicated that gene amplification of PIK3CA, AKT1 and AKT2 (but not of PI3KR1) and the loss of PTEN are common and may account for changes in the expression of the corresponding proteins. In conclusion, our results indicate that p110α overexpression represents the most frequent alteration within the PI3K/AKT pathway in OC. However, p110α overexpression may not be sufficient to activate AKT signalling and drive ovarian tumorigenesis since many tumors overexpressing PI3K presented at least one additional alteration.
Conflict of interest statement
Figures










Similar articles
-
Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.PLoS One. 2012;7(2):e30427. doi: 10.1371/journal.pone.0030427. Epub 2012 Feb 17. PLoS One. 2012. PMID: 22363436 Free PMC article.
-
PIK3CA alterations in Middle Eastern ovarian cancers.Mol Cancer. 2009 Jul 28;8:51. doi: 10.1186/1476-4598-8-51. Mol Cancer. 2009. PMID: 19638206 Free PMC article.
-
A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29. BJU Int. 2012. PMID: 23107319
-
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.Thyroid. 2010 Jul;20(7):697-706. doi: 10.1089/thy.2010.1646. Thyroid. 2010. PMID: 20578891 Free PMC article. Review.
-
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.Semin Cancer Biol. 2019 Dec;59:147-160. doi: 10.1016/j.semcancer.2019.05.012. Epub 2019 May 22. Semin Cancer Biol. 2019. PMID: 31128298 Review.
Cited by
-
PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers.Cell Death Dis. 2020 Sep 24;11(9):797. doi: 10.1038/s41419-020-02998-6. Cell Death Dis. 2020. PMID: 32973135 Free PMC article. Review.
-
CORO1C Regulates the Malignant Biological Behavior of Ovarian Cancer Cells and Modulates the mRNA Expression Profile through the PI3K/AKT Signaling Pathway.Cell Biochem Biophys. 2025 Jun;83(2):1819-1833. doi: 10.1007/s12013-024-01591-4. Epub 2024 Oct 21. Cell Biochem Biophys. 2025. PMID: 39433598
-
Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.Gynecol Oncol. 2016 Apr;141(1):2-9. doi: 10.1016/j.ygyno.2016.02.021. Gynecol Oncol. 2016. PMID: 27016222 Free PMC article. Clinical Trial.
-
NAC1/ACOX2 Axis as a Novel Therapeutic Target for Endometriosis-Related Ovarian Neoplasms.Int J Mol Sci. 2025 May 21;26(10):4938. doi: 10.3390/ijms26104938. Int J Mol Sci. 2025. PMID: 40430078 Free PMC article.
-
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035).Gynecol Oncol Rep. 2020 Feb 3;32:100546. doi: 10.1016/j.gore.2020.100546. eCollection 2020 May. Gynecol Oncol Rep. 2020. PMID: 32083163 Free PMC article.
References
-
- Fishman DA, Bozorgi K (2001) The scientific basis of early detection of epithelial ovarian cancer: the national ovarian cancer early detection program (NOCEDP). In Cancer Treatment and Research: Ovarian Cancer. In: Stack MS, Fishman DA editors. Boston: Kluwer Academic Publishers. 3–28. - PubMed
-
- Fader AN, Rose PG (2007) Role of surgery in ovarian carcinoma. J Clin Oncol 25: 2873–2883. - PubMed
-
- Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22: 255–288. - PubMed
-
- Feeley KM, Wells M (2001) Precursor lesions of ovarian epithelial malignancy. Histopathology 38: 87–95. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous